Is IMNM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Varegacestat FDA decision and launch, with revenue (fy2025) at ~$7M. The bear case rests on as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. Analysts covering it are spread from $30.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $30.00, +30.0% from the $23.08 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Varegacestat FDA decision and launch. The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. The most optimistic analyst target on IMNM is $40.00, +73.3% from the $23.08 price. That figure is only reachable if this thesis works close to its best case.

As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines. The most pessimistic published target is $30.00, +30.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Immunome, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Varegacestat FDA decision and launch) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Immunome is a clinical-stage targeted-oncology company developing cancer therapies. Its lead drug, varegacestat, is under FDA review for desmoid tumors, and it also runs an antibody-drug-conjugate and radiotherapy pipeline.

No. As a pre-commercial biotech it generates only minimal revenue (about $7 million in 2025) and posts recurring net losses, including roughly $53.8 million in the first quarter of 2026 as it funds research and development.

Varegacestat is Immunome's lead asset, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors. The company submitted a New Drug Application to the FDA in April 2026 after positive Phase 3 RINGSIDE results.